Numab Therapeutics Appoints Barbara Angehrn Pavik As CEO And Board Member, Succeeding Co-Founder David Urech Who Transitions To R&D Committee Chair

Numab Therapeutics AG, a biotechnology company developing a pipeline of multi-specific antibodies in immunology and oncology, announced a leadership transition. David Urech, Ph.D., co-founder and current Chief Executive Officer, will step down from his role as CEO and continue to serve on the company’s Board of Directors as Chair of the R&D Committee. As part of this planned succession, Numab has appointed Barbara Angehrn Pavik as Chief Executive Officer and member of the Board, effective immediately.

Angehrn Pavik brings more than 20 years of experience in the biopharmaceutical industry across both Europe and the United States. She most recently served as CEO of Asceneuron, a clinical-stage neurodegeneration company, where she successfully secured $100 million in Series C financing. Prior to Asceneuron, she was Chief Business Officer at Vifor Pharma, overseeing global commercial and corporate functions.

Urech said in a statement, “It has been an honor to be part of Numab’s journey since the foundation of the company in 2011, and I am incredibly proud of what we have accomplished together, building a world-class team, a robust pipeline, and a validated technology platform with the support of our investors and collaboration partners. I remain strongly committed to the company and will continue to support the team in my new role. Barbara brings Numab deep industry experience and a proven track record of success in drug development and commercialization across multiple therapeutic areas. I am confident that her leadership will support Numab’s strategic vision and accelerate efforts to deliver a new class of therapeutics to patients.”

Angehrn Pavik, CEO of Numab, mentioned, “Under David’s leadership, Numab has developed a world-class multi-specific antibody technology platform, established validating regional development and license agreements, and accomplished a notable $1.25 billion spin-out of its wholly owned subsidiary to J&J. The company has an exciting pipeline across multiple indications supported by a strong financial foundation, and I look forward to bringing the company to the next stage of growth.”

Earlier in her career, Angehrn Pavik spent over a decade at Amgen in oncology and hematology, before moving on to senior leadership positions with Onyx Pharmaceuticals and Exelixis. She also headed Stepstone Pharma, a venture dedicated to in-licensing opportunities outside the U.S. In addition to her new role at Numab, she serves as a Non-Executive Director at Bellevue Group and medmix Group AG. The transition marks an important step in Numab’s growth strategy as the company advances its antibody-based pipeline and prepares for future milestones in immunology and oncology.